Subcutaneous Infliximab Found Effective With or Without an Immunosuppressant

Patients who achieved a clinical response to subcutaneous infliximab showed no meaningful differences in outcomes ...

MARCH 5, 2025

Preventing Postoperative CD Recurrence and Predicting Recurrence Risk After Stopping Infliximab

One of my long-standing research interests is how to prevent CD recurrence after surgical resection.

FEBRUARY 21, 2025

Top-Down or Step-up Treatment For Newly Diagnosed CD, Standard or Intensified Infliximab Induction for ASUC

This month’s report examines two key studies on treatments for inflammatory bowel disease.

JANUARY 7, 2025

New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC

The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...

NOVEMBER 26, 2024

Patients Report Satisfaction Switching From Infliximab to Biosimilars

Most patients with IBD who switch from infliximab to an infliximab biosimilar report a positive experience, ...

OCTOBER 29, 2024

IBD Clinical Trials at a Crossroads

Inflammatory bowel disease clinical trials are facing headwinds, with challenges in recruitment and trial design.

OCTOBER 22, 2024

The ABCs of Optimizing Drug Sequencing for IBD

The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...

OCTOBER 13, 2024

Combination Advanced Therapy in the Treatment of Inflammatory Bowel Disease

The development of effective biologics and small molecule targeted therapies has revolutionized the treatment of ...

SEPTEMBER 5, 2024

Subcutaneous Infliximab or Vedolizumab For Maintenance Therapy in IBD; Fast-Acting Upadacitinib in Crohn’s

In this month’s The Regueiro Report, I highlight two studies on medications to treat inflammatory bowel ...

JUNE 19, 2024

Treating Patients With Inflammatory Bowel Disease and Obesity

An estimated 41% of the US population is obese, including 22% of individuals aged 12 to 19 years, while nearly 1 of ...

MAY 10, 2024

Top-Down Therapy Proves Its Worth in Crohn’s Disease

Adults newly diagnosed with active Crohn’s disease benefit from immediate treatment with advanced therapies, ...

APRIL 22, 2024

Highlights of Clinical Data on Subcutaneous Infliximab: Real-World Benefits

In the final chapter of this 3-chapter webinar series, Stephen B. Hanauer, MD, discusses findings from real-world ...

APRIL 3, 2024